US-based medical device company Nevro has announced the US Food and Drug Administration (FDA) approval and limited market release of HFX iQ with HFX AdaptivAI.
HFX AdaptivAI is a responsive, personalised pain management platform that powers the company’s HFX iQ spinal cord stimulation (SCS) system.
According to the company, HFX AdaptivAI is the only AI-powered technology to provide a superior level of personalised, responsive pain relief for patients suffering from chronic pain.
Nevro is planning to launch a full market release of its HFX iQ system with HFX AdaptivAI in the US, in the fourth quarter of this year.
Nevro CEO and president Kevin Thornal said: “Nevro is further establishing its position as the leading developer of data-driven solutions for pain management through the launch of HFX iQ with HFX AdaptivAI.
“HFX AdaptivAI delivers personalised pain relief, utilising AI and leveraging millions of data points and ten years of innovation and patient care.
“We believe this new solution is a major milestone, and it demonstrates our dedication to freeing patients from the burden of chronic pain through evidence-based therapies that transform patients’ lives.
“Importantly, HFX AdaptivAI puts patients in control of their pain relief while, at the same time, providing physicians the ability to monitor their patient’s pain journey, closing the loop that matters.”
According to Nevro, HFX AdaptivAI is engineered to maximize pain relief over time by continuing to optimise therapy even when more than 50% of pain relief has been achieved.
The technology creates customised therapy programmes in real time using direct patient input.
Its therapy optimisation capabilities allow the advanced Smart Power technology to reduce the patients’ need to charge their devices to as few as six times per year.
By collecting real-time quality of life (QoL) metrics and device data, the HFX AdaptivAI technology enables more impactful patient-clinician interactions.
With the launch of HFX AdaptivAI, physicians can remotely monitor each of their patients through their pain journey in real-time from its healthcare provider portal, said Nevro.
Nevro chief medical officer David Caraway said: “Chronic pain is a dynamic, biopsychosocial human condition unique to each individual. To effectively treat suffering – as perceived by each patient – therapies must be personalized based on the changing experience of pain.
“Only HFX AdaptivAI seeks to engage with the patient and personalize the SCS therapy in real time using evidence based on algorithms and multi-dimensional metrics of pain relief, function and satisfaction.”
